With an enhanced ability to visualize NMIBC lesions using Blue Light Cystoscopy (BLC®) , Dr. Shreyas Joshi M.D., M.P.H., recounts a recent case of a younger patient with recurrent non-muscle invasive bladder cancer (NMIBC) whose course of treatment was greatly influenced by the enhanced tumor detection provided by BLC.

Blue Light Cystoscopy (BLC®), which uses fluorescence to color tumors or lesions vivid pink, while healthy tissue remains blue, allows the visualization of bladder cancer that is not readily apparent when using White Light Cystoscopy (WLC) alone. Mild discoloration, flat lesions or papillary lesions that are not particularly raised can be missed when only WLC is used. With BLC, the borders of the harder-to-see areas can be seen more easily because of the fluorescence. Better visibility can mean a more complete resection. Kristen Scarpato, M.D., M.P.H., Associate Professor of Urology at Vanderbilt University Medical Center, who is experienced with Blue Light Cystoscopy (BLC®), shares her enthusiasm about the practical benefits of the improvements of the availability of BLC SAPHIRA equipment.